• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

循环成纤维细胞生长因子 23（FGF23）水平与癌症骨转移患者的预后。

Levels of Circulating Fibroblast Growth Factor 23 (FGF23) and Prognosis in Cancer Patients with Bone Metastases.

机构信息

Medical Oncology Department, Centro Hospitalar Universitário Lisboa Norte, Hospital de Santa Maria, Lisbon, Portugal.

Luís Costa Lab, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.

出版信息

Int J Mol Sci. 2019 Feb 6;20(3):695. doi: 10.3390/ijms20030695.

DOI:10.3390/ijms20030695
PMID:30736285
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6387099/
Abstract

The fibroblast growth factor (FGF) signaling pathway plays a key role in tumorigenesis and is recognized as a potential therapeutic target. In this study, the authors aimed to assess the impact of serum FGF23 levels in the prognosis of patients with cancer and bone metastases from solid tumors. A cohort of 112 patients with cancer and metastatic bone disease were treated with bone-targeted agents (BTA). Serum baseline FGF23 was quantified by ELISA and dichotomized in FGF23 and FGF23 groups. Additionally, the association between FGF23 and overall survival (OS) and time to skeletal-related events (TTSRE) was investigated. Baseline characteristics were balanced between groups, except for the median urinary N-terminal telopeptide (uNTX) level. After a median follow-up of 26.0 months, a median OS of 34.4 and 12.2 months was found in the FGF23 and FGF23 groups, respectively (multivariate HR 0.18, 95% CI 0.07⁻0.44, = 0.001; univariate HR 0.27, = 0.001). Additionally, TTSRE was significantly longer for patients with FGF23 (13.0 vs 2.0 months, = 0.04). Overall, this study found that patients with FGF23 at baseline had longer OS and TTSRE. Further studies are warranted to define its role as a prognostic biomarker and in the use of drugs targeting the FGF axis.

摘要

成纤维细胞生长因子 (FGF) 信号通路在肿瘤发生中起着关键作用，被认为是潜在的治疗靶点。本研究旨在评估血清 FGF23 水平对实体瘤伴癌性骨转移患者预后的影响。对 112 例接受骨靶向药物 (BTA) 治疗的伴转移性骨病的癌症患者进行了研究。采用 ELISA 法检测血清基线 FGF23，将其分为 FGF23 组和 FGF23 组。此外，还研究了 FGF23 与总生存期 (OS) 和骨骼相关事件时间 (TTSRE) 的关系。两组间基线特征除尿 N 末端肽 (uNTX) 中位数外均具有可比性。中位随访 26.0 个月后，FGF23 组和 FGF23 组的中位 OS 分别为 34.4 和 12.2 个月（多因素 HR 0.18，95%CI 0.07⁻0.44， = 0.001；单因素 HR 0.27， = 0.001）。此外，FGF23 组 TTSRE 明显更长（13.0 与 2.0 个月， = 0.04）。总之，本研究发现基线时 FGF23 水平较高的患者 OS 和 TTSRE 更长。需要进一步的研究来确定其作为预后生物标志物的作用以及在使用靶向 FGF 轴的药物方面的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a683/6387099/480a340c3044/ijms-20-00695-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a683/6387099/34fbc485203a/ijms-20-00695-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a683/6387099/480a340c3044/ijms-20-00695-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a683/6387099/34fbc485203a/ijms-20-00695-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a683/6387099/480a340c3044/ijms-20-00695-g002.jpg

相似文献

1
Levels of Circulating Fibroblast Growth Factor 23 (FGF23) and Prognosis in Cancer Patients with Bone Metastases.循环成纤维细胞生长因子 23（FGF23）水平与癌症骨转移患者的预后。
Int J Mol Sci. 2019 Feb 6;20(3):695. doi: 10.3390/ijms20030695.
2
Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study.成纤维细胞生长因子23（FGF23）与死亡率：路德维希港风险与心血管健康研究
Atherosclerosis. 2014 Nov;237(1):53-9. doi: 10.1016/j.atherosclerosis.2014.08.037. Epub 2014 Aug 28.
3
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.骨转换标志物作为前列腺癌、肺癌及其他实体瘤骨骼并发症的预测指标
J Natl Cancer Inst. 2005 Jan 5;97(1):59-69. doi: 10.1093/jnci/dji002.
4
FGF23-klotho axis, bone fractures, and arterial stiffness in dialysis: a case-control study.成纤维细胞生长因子 23-klotho 轴、骨折与透析患者动脉僵硬度：病例对照研究。
Osteoporos Int. 2018 Oct;29(10):2345-2353. doi: 10.1007/s00198-018-4598-2. Epub 2018 Jun 29.
5
Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease.炎症和成纤维细胞生长因子23水平升高是慢性肾脏病患者死亡的独立危险因素。
Kidney Int. 2017 Mar;91(3):711-719. doi: 10.1016/j.kint.2016.10.021. Epub 2016 Dec 22.
6
FGF23: mediator of poor prognosis in a sizeable subgroup of patients with castration-resistant prostate cancer presenting with severe hypophosphatemia?成纤维细胞生长因子23：在出现严重低磷血症的相当一部分去势抵抗性前列腺癌患者中，它是预后不良的介导因素吗？
Med Hypotheses. 2014 Oct;83(4):482-7. doi: 10.1016/j.mehy.2014.08.005. Epub 2014 Aug 11.
7
Fibroblast growth factor 23 predicts coronary calcification and poor prognosis in patients with chronic kidney disease stages 3-5D.成纤维细胞生长因子23可预测3-5D期慢性肾脏病患者的冠状动脉钙化及不良预后。
Ann Clin Lab Sci. 2015 Winter;45(1):17-22.
8
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.非去势转移性前列腺癌生存的预后因素：格拉斯模型的验证和新型简化预后模型的建立。
Eur Urol. 2015 Aug;68(2):196-204. doi: 10.1016/j.eururo.2014.09.022. Epub 2014 Sep 30.
9
Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors.预测转移性实体瘤老年患者总生存期和早期死亡率的血清生物标志物。
J Geriatr Oncol. 2019 Sep;10(5):749-756. doi: 10.1016/j.jgo.2019.03.015. Epub 2019 Apr 2.
10
Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure.成纤维细胞生长因子 23 与新出现和恶化心力衰竭患者的容量超负荷、治疗优化不良和预后相关的特征有关。
Int J Cardiol. 2018 Feb 15;253:84-90. doi: 10.1016/j.ijcard.2017.10.010.

引用本文的文献

1
Causal associations between fibroblast growth factors and breast cancer: Evidence from 2-sample Mendelian randomization analysis.成纤维细胞生长因子与乳腺癌之间的因果关联：来自两样本孟德尔随机化分析的证据。
Medicine (Baltimore). 2025 Aug 15;104(33):e43876. doi: 10.1097/MD.0000000000043876.
2
Deciphering aging-associated prognosis and heterogeneity in gastric cancer through a machine learning-driven approach.通过机器学习驱动的方法解析胃癌中与衰老相关的预后和异质性。
iScience. 2025 Mar 28;28(5):112316. doi: 10.1016/j.isci.2025.112316. eCollection 2025 May 16.
3
[Non-classical hormones from the fibroblast growth factor family].

本文引用的文献

1
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.雄激素受体信号通路非依赖性前列腺癌通过成纤维细胞生长因子信号得以维持。
Cancer Cell. 2017 Oct 9;32(4):474-489.e6. doi: 10.1016/j.ccell.2017.09.003.
2
Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER Breast Cancer.成纤维细胞生长因子受体 1（FGFR1）与雌激素受体α（ERα）的关联维持了配体非依赖性 ER 转录，并介导了 ER 阳性乳腺癌对雌激素剥夺的耐药性。
Clin Cancer Res. 2017 Oct 15;23(20):6138-6150. doi: 10.1158/1078-0432.CCR-17-1232. Epub 2017 Jul 27.
3
Tumour-induced osteomalacia.
[来自成纤维细胞生长因子家族的非经典激素]
Probl Endokrinol (Mosk). 2024 Nov 4;70(5):23-33. doi: 10.14341/probl13441.
4
Sea buckthorn and its flavonoids isorhamnetin, quercetin, and kaempferol favorably influence bone and breast tissue health.沙棘及其黄酮类化合物异鼠李素、槲皮素和山奈酚对骨骼和乳腺组织健康有积极影响。
Front Pharmacol. 2024 Oct 9;15:1462823. doi: 10.3389/fphar.2024.1462823. eCollection 2024.
5
A Rare Association Between Osteomalacia, Phosphaturic Mesenchymal Tumor, and Ovarian Cancer: A Case Report and Literature Review.骨软化症、磷酸尿基质肿瘤与卵巢癌罕见相关性：病例报告与文献复习。
Calcif Tissue Int. 2024 Aug;115(2):196-203. doi: 10.1007/s00223-024-01231-2. Epub 2024 May 28.
6
Emerging concepts on the FGF23 regulation and activity.关于成纤维细胞生长因子23（FGF23）调节与活性的新观念。
Mol Cell Biochem. 2025 Jan;480(1):75-89. doi: 10.1007/s11010-024-04982-6. Epub 2024 Apr 6.
7
Spectrum of PHEX Mutations and FGF23 Profiles in a Taiwanese Cohort With X-Linked Hypophosphatemia Including 102 Patients.台湾地区 X 连锁低磷血症患者 PHEX 基因突变谱及 FGF23 特征：包含 102 例患者的研究
In Vivo. 2024 Jan-Feb;38(1):341-350. doi: 10.21873/invivo.13444.
8
A New Approach to the Quantification of Fibroblast Growth Factor 23-An Array Surface Plasmon Resonance Imaging Biosensor.一种新的成纤维细胞生长因子 23 定量方法——阵列表面等离子体共振成像生物传感器。
Int J Mol Sci. 2023 Oct 18;24(20):15327. doi: 10.3390/ijms242015327.
9
The link between bone-derived factors osteocalcin, fibroblast growth factor 23, sclerostin, lipocalin 2 and tumor bone metastasis.骨源因子骨钙素、成纤维细胞生长因子 23、硬化蛋白、脂钙素 2 与肿瘤骨转移的关系。
Front Endocrinol (Lausanne). 2023 Feb 28;14:1113547. doi: 10.3389/fendo.2023.1113547. eCollection 2023.
10
Prognostic Value of Serum Soluble Klotho and Fibroblast Growth Factor-23 in Multiple Myeloma Patients.血清可溶性klotho和成纤维细胞生长因子-23在多发性骨髓瘤患者中的预后价值
Indian J Hematol Blood Transfus. 2022 Jul;38(3):454-463. doi: 10.1007/s12288-021-01470-5. Epub 2021 Jul 13.
肿瘤相关性骨软化症。
Nat Rev Dis Primers. 2017 Jul 13;3:17044. doi: 10.1038/nrdp.2017.44.
4
FGFR-targeted therapeutics for the treatment of breast cancer.用于治疗乳腺癌的成纤维细胞生长因子受体（FGFR）靶向疗法。
Expert Opin Investig Drugs. 2017 Mar;26(3):303-311. doi: 10.1080/13543784.2017.1287173. Epub 2017 Feb 6.
5
Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.成纤维细胞生长因子受体（FGF受体）和AKT激酶抑制剂联合治疗前列腺癌
Oncotarget. 2017 Jan 24;8(4):6179-6192. doi: 10.18632/oncotarget.14049.
6
Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents.骨吸收抑制剂治疗晚期癌症伴骨转移患者的骨转换标志物水平变化与临床结局。
Clin Cancer Res. 2016 Dec 1;22(23):5713-5721. doi: 10.1158/1078-0432.CCR-15-3086. Epub 2016 May 2.
7
FGF23 promotes prostate cancer progression.成纤维细胞生长因子23促进前列腺癌进展。
Oncotarget. 2015 Jul 10;6(19):17291-301. doi: 10.18632/oncotarget.4174.
8
The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis.FGF23-Klotho 轴：磷酸盐稳态的内分泌调节。
Nat Rev Endocrinol. 2009 Nov;5(11):611-9. doi: 10.1038/nrendo.2009.196.
9
Evolution of the Fgf and Fgfr gene families.Fgf和Fgfr基因家族的进化。
Trends Genet. 2004 Nov;20(11):563-9. doi: 10.1016/j.tig.2004.08.007.
10
FGF-23 is elevated by chronic hyperphosphatemia.慢性高磷血症会使成纤维细胞生长因子23（FGF-23）升高。
J Clin Endocrinol Metab. 2004 Sep;89(9):4489-92. doi: 10.1210/jc.2004-0724.